[Drugs in the Developmental Stage (Psychotropics)].
PubMed – May 01, 2023
Source: OpenAlex
Summary
A compelling new trend in drug development sees single medicines, like Psilocybin, investigated for multiple diseases concurrently. Despite past pharmaceutical withdrawals from neuroscience, innovative psychopharmacology is ushering in a new dawn. This involves novel drug mechanisms offering promise across various neuropsychopharmacological disorders, from Attention Deficit Hyperactivity Disorder to other complex psychiatric conditions. Such developments are reshaping pharmaceutical studies and practices, revitalizing drug development in psychology and medicine. This marks a significant shift in pharmacology.
Abstract
In recent years, it is common for a single drug to be developed for multiple diseases almost simultaneously, e.g., pimavanserin and psilocybin. Although there was gloomy news for the field of neuropsychopharmacology, such as withdrawal of the world's leading mega-pharmaceutical companies from the development of CNS drugs, drugs based on novel mechanisms of action have been investigated. This is a new dawn in the field of clinical psychopharmacology.